<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738071</url>
  </required_header>
  <id_info>
    <org_study_id>R-19-597</org_study_id>
    <nct_id>NCT04738071</nct_id>
  </id_info>
  <brief_title>International Multicenter Patent foRamen OVale &amp; strokE (IMPROVE) Registry</brief_title>
  <acronym>IMPROVE</acronym>
  <official_title>International Multicenter Patent foRamen OVale &amp; strokE (IMPROVE) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patent foramen ovale (PFO) is a prevalent cause of ischemic stroke and transient ischemic&#xD;
      attack (TIA) in young patients. Its role as a cause of cerebrovascular events in the older&#xD;
      population is more controversial because of other competing causes are more frequent in the&#xD;
      elderly. Recent randomized controlled trials (RCTs) have shown that PFO closure is associated&#xD;
      with a 59% relative risk reduction in the risk of recurrent ischemic stroke. As such, the&#xD;
      number of PFO closure procedures are expected to increase substantially in the upcoming&#xD;
      years. Real world data (RWD) informing on the medical management, the risk of stroke&#xD;
      recurrence, incident atrial fibrillation, and other outcomes in stroke patients with PFO,&#xD;
      with and without PFO closure, will become crucial for understanding how results from RCTs are&#xD;
      translated into clinical practice globally.&#xD;
&#xD;
      The IMPROVE (International Multicenter Patent foRamen OVale &amp; strokE) Registry is an&#xD;
      observational, multicenter, international registry of men and women with an ischemic stroke&#xD;
      or TIA. The aim is to enroll 8,800 patient-years at ≥50 sites in ≥20 countries.&#xD;
&#xD;
      The IMPROVE Registry will provide important information about the management and related&#xD;
      outcomes of patients with ischemic stroke or TIA and PFO throughout different regions of the&#xD;
      world and across a wide spectrum of healthcare systems.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">November 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 18, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Recurrent stroke</measure>
    <time_frame>Duration of follow-up (minimum of 3 months)</time_frame>
    <description>Recurrent hemorrhagic or ischemic stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incident atrial fibrillation</measure>
    <time_frame>Duration of follow-up (minimum of 3 months)</time_frame>
    <description>New diagnosis of atrial fibrillation after the index date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients undergoing PFO closure</measure>
    <time_frame>Within 12 months of the index diagnosis of PFO after the stroke or transient ischemic attack</time_frame>
    <description>Proportion of patients undergoing PFO closure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recurrent stroke or death</measure>
    <time_frame>Duration of follow-up (minimum of 3 months)</time_frame>
    <description>Recurrent hemorrhagic or ischemic stroke, or death</description>
  </other_outcome>
  <other_outcome>
    <measure>Recurrent stroke or myocardial infarction</measure>
    <time_frame>Duration of follow-up (minimum of 3 months)</time_frame>
    <description>Recurrent hemorrhagic or ischemic stroke, or myocardial infarction</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Stroke</condition>
  <condition>Patent Foramen Ovale</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <arm_group>
    <arm_group_label>Sex</arm_group_label>
    <description>Female and male patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age &gt;60 years of age</arm_group_label>
    <description>Patients younger or oder than 6o years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>World region</arm_group_label>
    <description>Patients from different world regions: North America, Europe, Asia, Latin America</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stroke vs. TIA</arm_group_label>
    <description>Index event: stroke vs. TIA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurocardiology Teams</arm_group_label>
    <description>Patients assessed by a neurocardiology team</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PFO closure</intervention_name>
    <description>PFO closure after stroke or transient ischemic attack</description>
    <arm_group_label>Age &gt;60 years of age</arm_group_label>
    <arm_group_label>Neurocardiology Teams</arm_group_label>
    <arm_group_label>Sex</arm_group_label>
    <arm_group_label>Stroke vs. TIA</arm_group_label>
    <arm_group_label>World region</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The IMPROVE registry aims to include patients from Asia, Europe, Oceania, North America and&#xD;
        Latin America. Academic, non-academic, urban and rural sites will be included. Principal&#xD;
        investigators will be neurologists, since a confirmed diagnosis of ischemic stroke or TIA&#xD;
        is mandatory before enrolment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA (all of the following criteria should be fulfilled)&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Ischemic stroke or TIA within 5 years and 1 year before inclusion in the registry.&#xD;
             Patients with cerebrovascular events occurred within one year before the inclusion in&#xD;
             the registry should be part of the prospective cohort.&#xD;
&#xD;
               -  Ischemic stroke is defined as:&#xD;
&#xD;
                    -  focal neurological deficit of central origin lasting ≥24 hours -except for&#xD;
                       death within 24hrs- with or without imaging confirmation of cerebral&#xD;
                       infarction; or&#xD;
&#xD;
                    -  focal neurological deficit of central origin lasting &lt;24 hours with&#xD;
                       corresponding imaging evidence of cerebral infarction; or&#xD;
&#xD;
                    -  focal neurological deficit of central origin lasting &lt;24 hours in patients&#xD;
                       receiving IV thrombolysis or endovascular thrombectomy with or without&#xD;
                       imaging confirmation of cerebral infarction; or&#xD;
&#xD;
                    -  non-focal encephalopathy lasting more than 24 hours -except for death within&#xD;
                       24hrs- with imaging evidence of cerebral infarction; or&#xD;
&#xD;
                    -  acute and permanent retinal ischemia of arterial origin.&#xD;
&#xD;
               -  TIA is defined as:&#xD;
&#xD;
                    -  focal neurological deficit of central origin lasting &lt;24 hours without&#xD;
                       corresponding imaging evidence of cerebral infarction in patients not&#xD;
                       receiving IV thrombolysis or endovascular thrombectomy.&#xD;
&#xD;
          -  Confirmed patent foramen ovale.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Venous stroke&#xD;
&#xD;
          -  Stroke mimics&#xD;
&#xD;
          -  Patients with incomplete data at 12 months after the index ischemic stroke or TIA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciano A Sposato, MD, MBA (PI)</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre, Western University (London, ON. Canada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Arauz, MD (Co-Pi)</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurology and Neurosurgery Manuel Velasco Suárez</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justina Diaz-Legaspe, PhD</last_name>
    <phone>+1 (519) 685-8500</phone>
    <phone_ext>35826</phone_ext>
    <email>justina.diazlegaspe@lhsc.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Ayan, MSc</last_name>
    <phone>+1 (519) 685-8500</phone>
    <phone_ext>35826</phone_ext>
    <email>diana.ayan@lhsc.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart &amp; Brain Lab, Western University</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justina Diaz-Legaspe, PhD</last_name>
      <phone>+1(519) 685-8500</phone>
      <phone_ext>35826</phone_ext>
      <email>justina.diazlegaspe@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Diana Ayan, MSc</last_name>
      <phone>+1(519) 685-8500</phone>
      <phone_ext>35826</phone_ext>
      <email>diana.ayan@lhsc.on.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Upon reasonable request and after the Approval of Western University Ethics Review Board</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

